Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

135
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
135
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

188
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
188
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

156
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

327
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
327
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

238
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
238
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

117
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
117

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

scRNA-seq based gene and cell dynamics behind the formation of the non-caseating granulomas.

Computational biology and chemistry·2026
Same author

Design, Synthesis, and Biological Evaluation of Tetrahydropyridine Analogues as Potent Antibiofilm Agents against <i>S. aureus</i>: In Vitro and In Silico Studies.

ACS omega·2026
Same author

Metatranscriptomics: A Tool for Clinical Metagenomics.

Omics : a journal of integrative biology·2024
Same author

A metagenome-wide association study of gut microbiome in patients with AMD, ASD, RA, T2D & VKH diseases.

Computational biology and chemistry·2024
Same author

<i>In-silico</i> mining to glean SNPs of pharmaco-clinical importance: an investigation with reference to the Indian populated SNPs.

In silico pharmacology·2023
Same author

Identification and annotation of milk associated genes from milk somatic cells using expression and RNA-seq data.

Bioinformation·2023

Related Experiment Video

Updated: Apr 25, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K

Single nucleotide polymorphism and its dynamics for pharmacogenomics.

Pramod Katara1

  • 1Center of Bioinformatics, University of Allahabad, Allahabad, 211002, India, pmkatara@gmail.com.

Interdisciplinary Sciences, Computational Life Sciences
|August 31, 2014
PubMed
Summary
This summary is machine-generated.

Pharmacogenomics uses genetic information to personalize medicine, improving drug efficacy and reducing adverse reactions. Identifying Single Nucleotide Polymorphisms (SNPs) is key, but challenges remain in cost and data interpretation.

More Related Videos

Design and Use of a Low Cost, Automated Morbidostat for Adaptive Evolution of Bacteria Under Antibiotic Drug Selection
10:50

Design and Use of a Low Cost, Automated Morbidostat for Adaptive Evolution of Bacteria Under Antibiotic Drug Selection

Published on: September 27, 2016

9.5K
Following the Dynamics of Structural Variants in Experimentally Evolved Populations
04:52

Following the Dynamics of Structural Variants in Experimentally Evolved Populations

Published on: February 3, 2023

1.2K

Related Experiment Videos

Last Updated: Apr 25, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K
Design and Use of a Low Cost, Automated Morbidostat for Adaptive Evolution of Bacteria Under Antibiotic Drug Selection
10:50

Design and Use of a Low Cost, Automated Morbidostat for Adaptive Evolution of Bacteria Under Antibiotic Drug Selection

Published on: September 27, 2016

9.5K
Following the Dynamics of Structural Variants in Experimentally Evolved Populations
04:52

Following the Dynamics of Structural Variants in Experimentally Evolved Populations

Published on: February 3, 2023

1.2K

Area of Science:

  • Genetics
  • Pharmacology
  • Personalized Medicine

Background:

  • Pharmacogenomics studies how genetic makeup influences drug response.
  • Personalized medicine aims to tailor treatments using genetic insights.
  • Current approaches often involve trial-and-error drug selection.

Purpose of the Study:

  • To highlight the role of pharmacogenomics in revolutionizing medical treatment.
  • To emphasize the importance of Single Nucleotide Polymorphisms (SNPs) in predicting drug response and disease susceptibility.
  • To discuss the need for accurate SNP identification and characterization for clinical application.

Main Methods:

  • Review of pharmacogenomic principles and their application.
  • Focus on the identification and characterization of Single Nucleotide Polymorphisms (SNPs).
  • Discussion of SNP-related study designs, including the SNP consortium protocol and HapMap project.

Main Results:

  • Pharmacogenomic approaches can reduce ineffective or toxic drug exposure.
  • SNPs are crucial for understanding individual susceptibility to illnesses and drug responses.
  • Ongoing efforts aim to identify common, relevant SNPs associated with disease risk and adverse drug reactions.

Conclusions:

  • Pharmacogenomics offers a personalized approach to treatment, moving beyond trial-and-error methods.
  • Accurate identification and characterization of SNPs are essential for their effective use as diagnostic tools.
  • Challenges in SNP research include sample size, cost, and result interpretation, despite advancements like HapMap.